Stocks

SpaceX plans to invest $100 billion to build a Starship complex in Louisiana and says the project could create 3,000 to 10,000 jobs. The company’s revenue rose to $18.7 billion in 2025, while operating cash flow reached $6.8 billion and it ended the year with $24.7 billion in cash and minimal short-term debt. In Q1 2026, revenue grew more than 15% year over year to $4.7 billion.

SanDisk has cut dozens of development roles at its Israel R&D centers while posting a sharp jump in fiscal Q4 revenue to $8.97 billion and data center revenue of $2.98 billion. The company said it expects as much as $10.8 billion in revenue this quarter and is targeting roughly 80% gross margins and mid-to-high-teens revenue growth through fiscal 2030. Shares have surged 2,809% over the past year, and the stock trades at 7.18 times forward earnings versus a sector average of 23.21 times.

Apple remains Berkshire Hathaway’s largest holding, underscoring confidence in the company’s compounding ability and strategic positioning. In fiscal Q3 2026, Apple extended its steady growth and confirmed that Chief Executive Officer responsibilities will transition to John Ternus.

Lincoln Pharmaceuticals set Sept. 30, 2026 as the record date for its 32nd annual general meeting, with the share transfer books to remain closed from Sept. 12 to Sept. 30. The company proposed a final dividend of 1.80 rupees per share of face value 10 rupees, equivalent to an 18% payout. For the quarter ended June 30, 2026, it reported consolidated net profit rising 30.90% year-on-year to 36.23 crore rupees, while total income increased 19.02% to 201.55 crore rupees. EBITDA for the quarter grew 32.29% to 51.70 crore rupees.

Pinterest said CFO Julia Brau Donnelly has resigned to pursue another opportunity and will remain in the role until October 30, 2026, to support an orderly transition. The company named Vikram Naidu, its vice president of finance and business operations, as interim CFO. Following the announcement, Pinterest shares fell about 3% in after-hours trading.

OpenText reported fiscal 2026 fourth-quarter revenue of US$1.35 billion, up 2.9% year over year. Cloud revenue rose 6% to US$503 million, while enterprise cloud bookings increased 24.1%. Adjusted EBITDA margin was 37.6% and adjusted EPS rose 26.8% to US$1.23. The stock trades around C$33, about 41% below its 52-week high.

Micron Technology shares have retreated from above $1,036 to around $935 even as the company’s fundamentals continue to improve. DRAM prices rose 58% to 63% sequentially in Q2, while HBM4E’s approaching 4:1 trade ratio could further constrain conventional DRAM supply by consuming more wafer capacity. Micron has secured $22 billion of commitments via strategic agreements, and major contracts extend through 2030 on take-or-pay terms.

AstraZeneca said its Phase 3 trial of an ATTR-CM drug developed with Ionis Pharmaceuticals failed to show additional benefit. Most patients in the study were already taking an oral “stabilizer,” and results showed the injectable “silencer” did not improve outcomes, weighing heavily on the overall trial. The setback is rippling beyond the two partners to other companies in the space, prompting a fresh reassessment of how injectable silencers stack up against oral stabilizers.

After the latest GTA 6 trailer was released, Take-Two Interactive shares rose 2.34% in after-hours trading and Sony Group shares gained 2.58%, reflecting a more upbeat market view of the game’s sales outlook. As of press time, Take-Two was trading at $238.45. The stock was still down 7.39% year-to-date.

Moderna’s investigational drug intismeran reported positive results in a Phase III melanoma trial, and some oncologists expect it could reach the market as early as early 2027. Management updated its estimated timeline for a potential approval to 2027, bringing forward expectations for the company’s return to stable growth. Argus Research upgraded Moderna shares, saying “the tide is turning.”